HRS-2189 + fluvastatin

HRS-2189 + fluvastatin is a combination drug currently under investigation for the treatment of advanced solid tumors, notably metastatic or unresectable breast cancer. HRS-2189 is a novel, orally administered small molecule antineoplastic agent developed by Shandong Suncadia Medicine, although its molecular mechanism of action and direct biological targets remain undefined[1][3]. Fluvastatin is an approved oral statin drug that inhibits HMG-CoA reductase, primarily used for lipid lowering and cardiovascular risk reduction. The rationale for the combination is to potentially enhance anti-tumor effects or provide synergistic benefits in oncology settings, but specific mechanistic synergy and combination effects are still being investigated in ongoing clinical trials[3].